dabrafenib plus trametinib for stage iii mutant melanoma
Published 6 years ago • 221 plays • Length 6:16Download video MP4
Download video MP3
Similar videos
-
4:45
combi-ad trial: adjuvant dabrafenib plus trametinib in patients with resected stage iii braf v60...
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
1:49
combi-ad: dabrafenib plus trametinib in advanced melanoma
-
5:13
dabrafenib plus trametinib improves melanoma patients’ survival
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
-
5:05
dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
-
2:08
phase 3 combi-d trial of dabrafenib plus trametinib in metastatic
-
7:05
improved response rate and survival with dabrafenib plus trametinib vs vemurafenib alone in melanoma
-
2:33
dr. sullivan discusses role of dabrafenib plus trametinib in melanoma
-
3:18
dabrafenib plus trametinib for the treatment of mnsclc
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
6:51
dabrafenib and trametinib plus pembrolizumab for braf-mutant melanoma
-
2:46
long-term outcomes with dabrafenib plus trametinib in braf v600-mutant melanoma
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma